Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
about
Modulation of DNA damage and repair pathways by human tumour virusesEpstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesisTransformation of the genital epithelial tract occurs early in California sea lion developmentModeling nasopharyngeal carcinoma in three dimensionsEpstein-Barr virus-induced up-regulation of TCAB1 is involved in the DNA damage response in nasopharyngeal carcinoma.Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.EBV reactivation as a target of luteolin to repress NPC tumorigenesis.Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin.Epstein-Barr virus infection and nasopharyngeal carcinoma.Correlations between Epstein-Barr virus and acute leukemia.Epstein-Barr virus BRLF1 induces genomic instability and progressive malignancy in nasopharyngeal carcinoma cells.Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing.Perspective: Contribution of Epstein-Barr virus (EBV) Reactivation to the Carcinogenicity of Nasopharyngeal Cancer Cells.Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
P2860
Q26825783-56BFFECB-73D6-4443-8E63-F9A84611E4E5Q28079510-E2E79B4C-A18C-4CD5-B383-1213D132CEEAQ28601256-895CED6D-45AD-488A-8B9E-102432FCF42AQ33599243-2D930349-4D79-4454-B0EC-64192FF4BC40Q33789662-41915E72-6B80-402A-B42E-F54FF8F65FA7Q35781438-EF06BA6C-718A-4A28-95FB-6933E4F0A521Q37086039-2690EBAC-5970-47AF-96A9-EC40F5081225Q37109915-3F7DC122-B9B4-4F26-85FA-40316413C24EQ37566280-96C3077E-A67C-4172-B9E5-4EA438A6AF8FQ40046633-B85A8B2C-0792-4834-8961-8650258AA5E9Q40322374-76350769-9D71-4FED-B06B-508212E756CBQ43206312-8439A6F8-27CB-4B84-ABE8-F04E008D36F7Q49787173-205D849C-EBDD-4E1A-877D-7C3EA9CD5882Q50043017-C4E13446-C52B-47B1-AC3F-F7955425CD1DQ54232271-7FB3FAD1-4ABF-4973-964A-A4965BE5A81AQ55518172-3E8F9981-BD9E-470B-A9A2-F0619F2D9850Q58711257-B1DB7445-535F-4653-85AE-9150E3C51996
P2860
Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@ast
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@en
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@nl
type
label
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@ast
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@en
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@nl
prefLabel
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@ast
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@en
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Epstein-Barr virus BALF3 media ...... y in nasopharyngeal carcinoma.
@en
P2093
Chih-Yeu Fang
Chung-Chun Wu
Hui-Yu Hsu
Jen-Yang Chen
Shih-Hsin Chiu
Shu-Ling Yu
Yen-Hung Chow
P2860
P304
P356
10.18632/ONCOTARGET.2323
P407
P577
2014-09-01T00:00:00Z